悦康药业
(688658)
| 流通市值：60.35亿 | | | 总市值：60.35亿 |
| 流通股本：4.50亿 | | | 总股本：4.50亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,181,150,785.77 | 556,037,071.94 | 2,446,086,968.93 | 1,759,106,131.97 |
| 营业收入 | 1,181,150,785.77 | 556,037,071.94 | 2,446,086,968.93 | 1,759,106,131.97 |
| 二、营业总成本 | 1,224,055,531.32 | 582,235,968.13 | 2,682,131,403.61 | 1,936,291,861.68 |
| 营业成本 | 522,710,502.75 | 239,489,908 | 1,218,344,224.54 | 889,487,883.35 |
| 税金及附加 | 19,243,241.9 | 8,620,113.51 | 38,416,344.43 | 28,423,444.71 |
| 销售费用 | 343,777,060.4 | 183,401,679.27 | 703,899,243.35 | 503,822,735.77 |
| 管理费用 | 121,083,752.21 | 55,179,083.47 | 266,972,832.16 | 187,706,427.97 |
| 研发费用 | 210,045,664.54 | 91,687,640.44 | 441,205,802.99 | 316,552,600.23 |
| 财务费用 | 7,195,309.52 | 3,857,543.44 | 13,292,956.14 | 10,298,769.65 |
| 其中:利息费用 | 8,197,291.6 | 4,323,557.13 | 21,653,299.28 | 16,572,381.33 |
| 其中:利息收入 | 1,633,919.09 | 636,539.35 | 8,857,163.49 | -6,487,974.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,284,430.91 | 1,349,550.61 | 6,040,391.9 | 301,842.59 |
| 加:投资收益 | 2,965,793.86 | 779,942 | 3,461,129.19 | 2,437,656.3 |
| 资产处置收益 | 270,846.96 | 283,271.88 | 924,147.58 | 3,106,247.76 |
| 资产减值损失(新) | -70,280,994.8 | -11,765,945.74 | -41,543,453.77 | -19,321,293.37 |
| 信用减值损失(新) | -1,254,757.97 | 715,949.93 | 3,621,536.25 | 6,993,424.2 |
| 其他收益 | 13,383,963.97 | 4,880,745.24 | 29,094,959.63 | 19,964,889.37 |
| 四、营业利润 | -99,104,324.44 | -29,955,382.27 | -234,445,723.9 | -163,702,962.86 |
| 加:营业外收入 | 364,787.11 | 29,867.8 | 1,580,712.41 | 678,922.28 |
| 减:营业外支出 | 3,045,309.67 | 636,333.12 | 4,187,444.36 | 1,787,262.69 |
| 五、利润总额 | -101,784,847 | -30,561,847.59 | -237,052,455.85 | -164,811,303.27 |
| 减:所得税费用 | 18,655,714.9 | 7,465,657.02 | 37,763,734.96 | -10,208,565.76 |
| 六、净利润 | -120,440,561.9 | -38,027,504.61 | -274,816,190.81 | -154,602,737.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -120,440,561.9 | -38,027,504.61 | -274,816,190.81 | -154,602,737.51 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -104,898,920.14 | -33,106,026.51 | -262,389,860.99 | -147,977,976.65 |
| 少数股东损益 | -15,541,641.76 | -4,921,478.1 | -12,426,329.82 | -6,624,760.86 |
| 扣除非经常损益后的净利润 | -112,520,697.87 | -37,344,424.7 | -287,945,988.91 | -167,500,357.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.24 | -0.07 | -0.59 | -0.33 |
| (二)稀释每股收益 | -0.24 | -0.07 | -0.59 | -0.33 |
| 八、其他综合收益 | -8,018.42 | - | -28,239.37 | - |
| 归属于母公司股东的其他综合收益 | -8,018.42 | - | -28,239.37 | - |
| 九、综合收益总额 | -120,448,580.32 | -33,106,026.51 | -274,844,430.18 | -154,602,737.51 |
| 归属于母公司股东的综合收益总额 | -104,906,938.56 | -33,106,026.51 | -262,418,100.36 | -147,977,976.65 |
| 归属于少数股东的综合收益总额 | -15,541,641.76 | - | -12,426,329.82 | -6,624,760.86 |
| 公告日期 | 2026-08-21 | 2026-04-30 | 2026-03-21 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |